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Abstract We studied the effects of zoledronic acid (ZA) and leuprore-
lin acetate (LA) separately and combined on a human cell line derived
from a bone metastasis of prostatic adenocarcinoma (PC3). In particu-
lar, we focused on the effects that drugs given singularly or in associ-
ation may play on tumor evolution and metastatization. Cell prolifera-
tion, 2D- and 3D-migration were studied in basal conditions and under
attractive stimuli exerted by bone marrow mesenchymal stem cells
(BM-MSC). Either drug decreased PC3 proliferation, though ZA was
much more cytotoxic than LA. However, LA cytotoxic concentrations
are higher than those usually reached in vivo. Subtoxic concentration
of either drug inhibited migration especially under BM-MSC medium
stimuli via an Akt-dependent mechanism. The capability of either drug
to inhibit cellular migration is in line with their well-known effect in
limiting metastatization. Intriguingly, no additive effect on the antipro-
liferative activity or in hindering migration is observed when the drugs
are administered concomitantly, compared to the effects of each drug
alone.
Keywords gonadotropin-releasing hormone analogue; bisphospho-
nate; prostate cancer; cytotoxicity; metastatization
1. Introduction
GnRH receptors are present both in prostatic malignant
tissue and carcinoma derived cell lines, suggesting that
GnRH analogues such as leuprorelin acetate (LA) [28],
normally used to treat advanced prostate cancer (PCa),
can exert a local action [10]. An inhibition of proliferative
activity in presence of GnRH agonists has been found in
androgen independent and androgen dependent prostatic
cancer derived cell lines [23] and in epithelial cells isolated
from prostatic tumors [2].
Moreover, LA antagonizes the metastatic behavior of
both androgen-independent cell lines, DU145 and PC3, by
decreasing their capacity to invade a reconstituted matrix
and to migrate in response to haptotactic stimuli [5]. Bone
is the preferential site for PCa metastases. Bone metastases
likely depend on crosstalk between metastatic cells, bone
matrix, osteoblasts and osteoclasts, and cellular components
of the bone marrow microenvironment. Among these,
bone marrow mesenchymal stem cells (BM-MSCs) play a
paramount role in the so-called metastatic niche [14,22].
In particular, BM-MSC paracrine factors may allow tumor
cells to access cellular niches favoring tumor cell survival
and growth [14,22].
Administration of IV bisphosphonates, such as zole-
dronic acid (ZA), can prevent bone loss and modulate tumor
cell migration and invasion [11] in breast and prostate
cancer bone metastases in patients treated with GnRH
agonists [20].
The beneficial effects of bisphosphonates in PCa
patients are attributed to their inhibitory activity on
osteoclast-mediated bone resorption, which is markedly
increased in lytic and in blastic metastatic bone disease [9].
They likely act on two essential stages of metastatic process:
(1) tumor cell adhesion to bone extracellular matrices and
(2) invasion through extracellular matrix, via modulation of
cell adhesion molecules and extracellular matrix interacting
molecules [4].
In addition to their antiosteoclast effects, bisphospho-
nates directly inhibit in vitro the growth of breast [6], pan-
creas [30], and prostate cancer cells, in a concentration- and
time-dependent manner [17].
Despite the absence, to our knowledge, of in vitro and
achieved preclinical studies investigating any potential
interaction in the coadministration of GnRH analogues and
bisphosphonates, this association is considered the gold
standard of metastatic PCa therapy. Particularly, pharmaco-
dynamic drug interactions could be the result of overlapping
mechanisms of action. Therefore, we wondered whether
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drug interactions can positively or negatively modify both
drug effect and/or toxicity. A better understanding of these
potential interplays could be used to increase the therapeutic
effect of a combination regimen or to minimize its toxicity.
We, therefore, examined the antiproliferative and antimigra-
tory effect of a GnRH analogue, LA, and of a bisphospho-
nate, ZA, alone or in combination, on PC3 cells in vitro, in
basal and stimulated conditions, obtained by exposing PC3
cells to the medium conditioned by BM-MSCs. Moreover,
we analyzed the role of these two drugs on Akt phosphoryla-
tion, which is one of the most notable mechanisms involved
in cell proliferation and migration [16]. PC3 cells, isolated
from bone metastases of PCa, were chosen because they
mimic the castration-resistant phase of PCa patients treated
with both GnRH analogues and bisphosphonates [15] and
because they are thoroughly recognized as a representative
of a highly metastatic PCa cell line, on account of, among
other aspects, their lack of AC-tubulin [29] and increased
levels of β1 integrins and integrin-induced autophosphory-
lation of FAK [18]. PC3 cells are frequently used to study
PCa bone metastasis both in vivo and in vitro [12,13].
With this in vitro study, besides confirming the direct
cytostatic effect of either drugs (ZA or LA), we also show,
for the first time, that both drugs limit cell migration induced
by BM-MSCs and that there is no additive effect when these
drugs are used concomitantly. Therefore, we suggest that it
is worthwhile to consider a therapeutic regimen in which the
two classes of drugs are included in early stages when there
are not yet signs of bone metastases in patients with PCa.
2. Materials and methods
All reagents were purchased from Sigma (St. Louis,
MO, USA) unless otherwise stated. Tissue culture plas-
ticware was from Falcon (Franklin Lakes, NJ, USA).
Zoledronic acid [1-hydroxy-2-(1H-imidazol-1-yl)ethane-
1,1-diyl]bis(phosphonic acid) was generously provided by
Novartis (Surrey, UK) and leuprorelin acetate
(N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-
1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxo-pentan-2-
yl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-
butyl]carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamoyl]-
2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-
yl)ethyl]carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxo-
pyrrolidine-2-carboxamide).
was from Takeda (Osaka, Japan)
2.1. Cell culture
PC3 cells (human androgen-independent cells derived from
a bone metastasis of prostatic adenocarcinoma) were pur-
chased from ATCC (Rockville, MD, USA).
Cells were maintained at 37 °C in a humidified 5% CO2
atmosphere in RPMI 1640 containing 10 mL/L penicillin
and streptomycin solution, NaHCO3 2 g/L (7.5% w/v), 10%
Fetal Bovine Serum (FBS) decomplemented for 30 min at
55 °C.
2.2. Bone marrow mesenchymal stem cells (BM-MSC) iso-
lation and production of BM-MSC conditioned medium
Bone marrow cells were harvested from femurs of adult rats
as detailed in the work of Raimondo et al. [25]. Animals
received care in accordance with the Italian law (DL-116,
27 January 1992), which complies with the Guide for the
Care and Use of Laboratory Animals by the US National
Research Council.
We previously demonstrated that BM-MSCs isolated
with this procedure are CD90+ and CD34/CD45- and that
under opportune stimuli they can differentiate [7,25]. We
also previously reported that BM-MSCs stimulate PCa cell
migration [22]. BM-MSCs were therefore included in the
present study according to the described protocols.
BM-MSC conditioned medium was collected after three
days of culture, centrifuged to eliminate cells and cellular
debris, and freshly used or frozen [22].
2.3. Proliferation assay
PC3 cells were seeded into flat-bottomed 96-well mi-
croplates (1,000/100µL culture medium/well) and allowed
to attach overnight in complete medium before drugs
addition. Drugs were added to culture medium, alone or in
combination, testing various concentrations from 2.5µM
to 50µM (ZA) [19] and 0.5µM to 100µM (LA) [23] for
24–96 h, according to protocols.
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide) assay was performed as described by
Mognetti et al. [21]. Data (mean ± standard errors) were
the average values of 8 replicates. Each experiment was
repeated thrice. Cell viability was expressed as percentage
of living cells with respect to controls.
2.4. 2D migration assay-wound healing
PC3 cells were seeded in a 6-well plate at 30,000 cells/well.
When confluent, we performed a cross “wound” in each well
with a p1000 tip [8], then wells were washed thrice with PBS
and medium replaced without (control) or with single (ZA
5µM and LA 100µM) or combined drugs (ZA 5µM plus
LA 100µM).
We photographed “wounds” on time-laps every 45 min
to highlight migration until a maximum of 6 h and, as a final
time point, at 24 h.
Experiments were repeated three times and every time
five different points for each experimental condition were
considered.
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Figure 1: Proliferation assay. Effect of ZA (a) and LA (b) on PC3 proliferative activity. Arrows show IC50. ∗ = P < .05
versus control conditions.
Images were analyzed using ImageJ software: migration
was evaluated considering the reduction of wound area, and
then compared to controls.
2.5. 3D migration assay
The transwell migration assay was used to measure the
three-dimensional movements of cells. Migration assays
were performed in transwells (BD Falcon cell culture inserts
incorporating polyethylene terephthalate (PET) membranes
with 8.0µM pores, 1×105 pores/cm2).
When assessing spontaneous migration, culture medium
was RPMI. When assessing migration in stimulated condi-
tions, control medium was αMEM. When tests were per-
formed in the presence of Wortmannine, cells were preincu-
bated for 30 min at 37 °C with 100 nM.
Cells (105) resuspended in 200µL of culture medium
containing 2% FBS were seeded in the upper chamber
of a transwell. The lower chamber (a 12-well plate) was
filled with fresh or conditioned culture medium containing
2% FBS and placed in the incubator. After 6 h, cells
were treated as detailed by Gambarotta et al. [8]. Wells were
photographed using a BRESSER MikroCam 3 Mpx camera,
with an optical microscope (Leica DC 100) at 100×. Five
pictures were randomly chosen per well, and used to count
the migrated cells with ImageJ software using cell-counter
plug-in. Results from different experiments (performed at
least three times in duplicate) were expressed as mean± SE.
In order to avoid any cytotoxic effect of potentially con-
founding migration results, we performed a cytotoxicity test
as previously described at the same time and same condi-
tions of every migration test.
2.6. Western blotting
Since Akt phosphorylation plays a role of paramount
importance in cell migration [16], we tested the effects of
ZA or LA on the phosphorylation levels of Akt (expressed
as pAkt/Akt ratio) in the presence of studied drugs and in
the presence of Wortmannine (100 nM), used as a positive
control.
Cells were seeded in 10 cm diameter Petri dishes,
cultured until subconfluence, when drugs were added (ZA
5µM and LA 100µM). After 6 h incubation, cells were
collected and treated as detailed by Mognetti et al. [22] and
immunoblotted according to Penna et al. [24]. In parallel
proliferation tests—as previously described—performed
in the same culture conditions in order to exclude any
confounding element, no significant cytotoxicity was
appreciable at the chosen concentration after 6 h incubation.
Blots were probed with primary polyclonal antibody
(Cell Signaling Technology, Danvers, MA, USA) suspended
in TBS Tween 0.1%: anti-Akt (mouse, 1:800), anti-pAkt
(Ser473, rabbit, 1:500), and anti-Vinculin (developed in
rabbit, Sigma). Vinculin was used as an internal control.
HRP-conjugated anti-mouse (Amersham-GE Health-
care, Buckinghamshire, UK) and anti-rabbit (Santa Cruz
Biotechnology) were diluted (1:6000 and 1:8000, resp.)
in TBS Tween 0.025%. Bands were quantified using the
ImageJ software.
Phosphorylation levels of Akt were expressed as ratio
pAkt/Akt. All data were expressed as percentage modifica-
tion relative to control conditions.
2.7. Statistics
Statistical analyses were performed by one-way or two-way
ANOVA, and P < .05 was considered significant. If not
differently specified, data are expressed as percentage mean
± standard deviation compared to control.
3. Results
3.1. Inhibition of proliferative activity
ZA strongly inhibited cell proliferation (Figure 1(a)); cell
growth was inhibited after 48 h already by 20µM ZA, and
even more strikingly after 72 h culture.
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Figure 2: Proliferation assay. Effect of the simultaneous administration of LA (100µM, constant concentration) plus ZA
(2.5 to 40µM, dotted line) on PC3 proliferation compared to cytotoxicity of 100µM LA alone (triangle) and ZA alone (2.5
to 40µM, black line). Results are expressed as percentage of control ±SE.
Yet, no significant effect on cell proliferation was
induced by LA at any concentration tested in the first
72 h (Figure 1(b)). A significant inhibition was induced by
concentrations greater than 10µM only after 96 h treatment
(Figure 1(b)).
The simultaneous presence of the two drugs neither
increased nor decreased the effect of the single drugs at
any considered time point. An example is reported in
Figure 2, where a constant amount of LA (100µM, i.e.,
the highest concentration tested) was added to increasing
concentrations of ZA. As in Figure 1, LA (100µM) alone
did not induce appreciable variation of cell proliferation
(triangle in Figure 2).
To further analyze drug interactions, the concentrations
of LA (from 1µM to 100µM) were increased in the
presence of 5µM ZA, and cells were grown for 72 h in the
presence of the two drugs. Also in this case no significant
variation of cell growth was observed after the addition of
increasing concentrations of LA (data not shown).
3.2. Inhibition of migratory activity
Two-dimensional migration was inhibited both by ZA and
LA, with significant effects already visible after 1.5 h (Fig-
ure 3). The simultaneous presence of the two drugs did not
relevantly change the cell behavior, except between 2 and
3 h incubation, when it significantly quenched LA effects.
On the other hand, no significant difference was evidenced
between the drug combination and ZA alone, or between
the two single drugs. The same trend is respected after 24 h
incubation, when the three conditions are significantly dif-
ferent from control but not different between each other.
Since no difference in the rate of migration was
evidenced when experiments were performed in RPMI
or αMEM, we pooled data and globally referred to them as
control.
Three-dimensional migration was significantly inhibited
after 3 h (data not shown) and 6 h (Figure 4) by ZA and by
LA, both in basal and in stimulated conditions. Again, the
concurrent presence of the two drugs did not increase their
inhibitory effect (even, it quenched LA effect).
In the same conditions, we measured Akt phosphoryla-
tion and revealed that both ZA and LA decrease it in basal
and stimulated conditions.
Inhibition of Akt phosphorylation and that of 3D
migration are not proportional (no direct correlation could
be established), nevertheless the trend is clearly the same.
Importantly, 3D migration rate was decreased by the
inhibition of Akt phosphorylation (100 nM Wortmannine),
both in basal and stimulated conditions.
4. Discussion
A major source of morbidity in patient with prostate cancer
is the widespread bone metastases, which often grow in a
castration-resistant manner and still are a major topic in the
research for novel treatment strategies. Monotypic in vitro
cultures are commonly employed to study drug effects on
cell proliferation and migration. Cell lines are still the main
experimental model used in many publications, despite the
fact that animal models have become widely available in
recent years. PC3 cells are androgen independent, prolifer-
ate normally in androgen deprived media in vitro and pos-
sess high migratory capability. In addition, PC3 xenograft
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Figure 3: Two-dimensional migration. The wound healing was quantified every 45 min in time laps up to 6 h (a) and at 24 h
(b), and is displayed as basal conditions (CTRL) or as the effect of 5µM ZA, 100µM LA or a combination of both drugs
(5µM ZA + 100µM LA). Data are expressed as relative to control conditions±SE. Experiments were performed three times
in duplicate. P values are reported in the underlying table; n.s. means difference being not statistically significant.
Figure 4: Three-dimensional cell migration and Akt phosphorylation. Effect of 5µM ZA, 100µM LA, the combination
of both drugs (5µM ZA + 100µM LA) and 100 nM Wortmannine (W) on PC3 3D migration (black bars) and Akt
phosphorylation (grey bars) in basal (CTRL) and stimulated (CM) conditions. Data are expressed as percentage towards
basal conditions (CTRL). ∗= P < .05 versus control conditions. #= P < .05 versus conditioned medium (CM).
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tumors proliferate rapidly and are quite invasive. For those
reasons, PC3 cells are thoroughly recognized as an appro-
priate model for the study of the more aggressive forms of
PCa.
The use of complementary assays, such as wound
healing and transwell motility assays, is commonly used
to assess in vitro metastatic potentials [31]. Moreover, our
coculture system permits to study the drug effects on the
migration of PCa cells in conditions that more resemble the
in vivo tumor microenvironment, by providing the tumor
cells with contextual signals. This model has already been
validated [22] and proved to be reliable in reproducing the
chemotactic effect exerted by BM-derived cells on PCa.
This in vitro study strongly supports that ZA has cyto-
toxic effects on a PCa cell line derived from a bone metas-
tases, an effect that is much less evident for LA. Yet, either
drug limits cell migration in a similar extent. Intriguingly,
no relevant additive effects can be appreciated between the
two drugs in affecting cell migration and proliferation. The
lack of additive effects as well as the similar effects on Akt
phosphorylation suggests that diminution of the effect of
every single drug is highly unlikely in vivo.
A direct cytotoxicity of ZA has been already de-
scribed [17], though never in combination with LA. In our
hands, ZA toxicity was already significant after 48 h culture
at 20µM, regardless of LA cotreatment. In a previous
study [19], the toxicity of ZA was observed at lower
concentrations probably because of different experimental
conditions. It is of note that, in vivo, the effective local con-
centrations of bisphosphonates at sites of active bone resorp-
tion are much higher than serum levels and may reach up to
10−3 M in the resorption lacunae [27]. It is possible there-
fore to infer that in treated patients the close association of
cancer cells with actively resorbing osteoclasts and the bone
matrix will result in exposure of tumor cells to bisphospho-
nates concentrations sufficient to induce their apoptosis [17].
It is much more difficult, on the other hand, to expect,
in vivo, a direct cytotoxicity attributable to LA, since con-
centrations needed, as defined by our study and by other
groups [5,23], cannot be reached with therapeutical dosages.
When used at subtoxic concentration, both ZA and
LA significantly inhibit 2D migration, already after 1.5 h.
This property is even more striking when cells are exposed
to a chemotactic stimulus. Intriguingly, this phenomenon
is probably very close to what happens in vivo, where
bone microenvironment strongly influences cancer cells
motility [3,32].
Caraglia et al. [1] described a decrease in the activation
of PI3K/Akt pathway following treatment with ZA, suggest-
ing that it may act upstream of the metastasis, by inhibiting
PCa cell migration towards metastatic sites through inter-
ference with this pathway mostly implicated in cell migra-
tion [16]. Our study concurs with that of Caraglia et al. by
suggesting that inhibition of migration provoked by ZA and
LA might be mediated by inhibition of Akt phosphoryla-
tion, which, on the other hand, is increased when cells are
exposed to a chemotactic stimulus fostering their motility.
We conclude that ZA is more cytotoxic than LA in vitro.
However, due to the effective dosage of the two drugs, we
suggest that such an effect is likely, in vivo, for ZA only.
Nevertheless, both compounds strongly reduce basal and
BM-MSC stimulated cell motility in vitro. Therefore, they
are likely implicated in reduction of PCa cells motility,
with great fall out on bone metastases formation. This anti-
tumoral activity is in line with the recently demonstrated
beneficial effects of these two compounds in PCa patients
with bone metastases [26].
The clinical implications might be the possible increase
in GnRH analogues dosage in castration-resistant patients,
to increase its antiproliferative effect, and an early use of
ZA before the appearance of the metastasis, with the aim of
inhibiting PCa cell proliferation, promoting apoptosis and
preventing cell migration.
Importantly, when these two drugs are used in associ-
ation we do not observe unfavorable interactions between
them on the studied parameters. However, we cannot rule
out that association treatment regimen that enhances or
inhibits the effect of the two drugs exists in vivo. The
experience with this association has scarcely been studied
in vivo under a pharmacological point of view; therefore
studies such as ours are needed.
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